Amicus Therapeutics (FOLD) Tops Q3 EPS by 3c, Beats on Revenue
Tweet
Share
E-mail
Get Alerts FOLD Hot Sheet
Price: $14.49 --0%
Financial Fact:
Total operating expenses: 46.72M
Today's EPS Names:
HMR, RZLV, ZEPP, More
Financial Fact:
Total operating expenses: 46.72M
Today's EPS Names:
HMR, RZLV, ZEPP, More
Join SI Premium – FREE
Amicus Therapeutics (NASDAQ: FOLD) reported Q3 EPS of $0.06, $0.03 better than the analyst estimate of $0.03. Revenue for the quarter came in at $169.06 million versus the consensus estimate of $165.44 million.
For earnings history and earnings-related data on Amicus Therapeutics (FOLD) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- UBS Assumes Interactive Brokers Group (IBKR) at Neutral, 'A Best-in-Class, Yet Fairly Valued Brokerage'
- PG&E downgraded by Wells Fargo, BMO as California wildfire reform falls short
- BofA Securities Upgrades Lloyds Banking Group Plc. (LLOY:LN) (LYG) to Buy
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
